As the first quarter of 2024 closed, the biopharma sector wasn't just riding the wave of excitement that accompanies groundbreaking scientific discoveries—it was also navigating the tumultuous waters of the financial markets. With M&A activity surging by a staggering 71 percent in &
Throughout 2023 and 2024, the U.S. Food and Drug Administration (FDA) played a pivotal role in the pharmaceutical and biotechnology sectors, not only by approving a significant number of new drugs but also by pushing the boundaries of innovation. These two years were marked by a notable surge in
As the field of medical research forges ahead, certain pioneering companies are facing a formidable hurdle. MMJ BioPharma Labs and MMJ International Holdings, at the forefront of developing cannabis-based pharmaceuticals, find themselves entangled in a problematic scenario with the Drug Enforcement
Cancer treatments have long been a complex array of procedures with varying degrees of success. However, groundbreaking research from the University of Houston, spearheaded by Navin Varadarajan and his team, has shone a light on a new horizon for cancer therapy. They have identified CD8-fit T
Recent actions by U.S. House lawmakers have cast a spotlight on GenScript, a Chinese Contract Development and Manufacturing Organization (CDMO), and its cell therapy division, Legend Biotech, amidst concerns of potential Chinese Communist Party (CCP) influence within the American biotech realm.
As the battle against cancer continues, one particular area showing remarkable strides is colorectal cancer research and treatment. With over 195 key players in the industry, a testament to the competitive yet collaborative nature of the field, advancements are moving at an incredible pace. From
In the dynamic landscape of the stock market, few stories encapsulate the sheer unpredictability like that of Sunshine Biopharma Inc. (SBFM). From dizzying peaks to harrowing valleys, SBFM's fiscal journey over the past year reads like a thrilling financial epic. With the highest crest at
The battle against cancer is one that has engaged the global medical community for decades, and with the emergence of Chimeric Antigen Receptor (CAR) T-cell therapy, we stand on the precipice of a significant revolution in the way cancer is treated. This immunotherapy transforms a patient's
In the ever-evolving landscape of pharmaceuticals, the debate over regulatory data protection (RDP) is intensifying. As the Belgian Presidency of the Council of the EU approaches its twilight, policymakers are grappling with how to balance the imperatives of fostering pharmaceutical innovation with
The landscape of biopharmaceutical manufacturing in Ireland has recently welcomed an impressive addition with the inauguration of the National Institute for Bioprocessing Research and Training's (NIBRT) new facility. This state-of-the-art establishment in Dublin, conceived with a robust €21 m
